City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.
Joanne Mortimer, MD, director of the women's cancer program at City of Hope, discusses early findings of a study on the oral selective estrogen receptor downregulator (SERD) ZN-c5 being presented at the 2020 San Antonio Breast Cancer Symposium.
Transcript
Your poster presentation is a dose escalation study of the novel oral SERD ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer. Can you discuss the key findings and the role of selective estrogen receptor degraders in breast cancer treatment?
Currently, we have 1 drug that is in the category of SERDs—selective estrogen receptor downregulators—and that's fulvestrant, or Faslodex is the trade name. And this is a shot that's 5 cc's in each buttock once a month, and you get an extra dose in the first month. And it's a very effective drug and it's effective in particular types of estrogen receptor-positive breast cancers over other oral agents that are available. So it's a very important drug in the management of women who have metastatic, hormone receptor-positive breast cancer.
The problem with the drug is that it requires that the patient come in and that they have a 5-cc injection each buttock, which is not pleasant. Otherwise, this drug is very well tolerated with very few side effects. The poster is about an oral agent in this category that hopefully will supplant or maybe add to our armamentarium of hormone therapies in metastatic breast cancer. This poster provides the results of 15 patients who have started this therapy, and they were heavily pretreated. The median number of previous hormone treatments was 3, all had received at least 1 dose of chemotherapy. Ultimately, 10 of the 15 women had at least stabilization of their disease. This is a very optimistic finding for a new drug that maybe will not require the patient to come in to get an intramuscular injection, and so there's reason for optimism with this agent.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More